U.S. FDA RMAT Designations Surge to 165 Total, with Rocket Pharmaceuticals (5) and CRISPR Therapeutics (4) Leading the Way

July 19, 2026

BioInformant USA

Overview

As of July 15, 2026, the cumulative number of Regenerative Medicine Advanced Therapy (RMAT) designations publicly announced by the U.S. FDA has reached 165. Rocket Pharmaceuticals and CRISPR Therapeutics are notably leading in this field, with 5 and 4 RMAT designations respectively. RMAT designation is designed to facilitate the expedited regulatory approval of regenerative medicine and gene therapy products, strongly indicating progress in developing innovative treatments for serious diseases. This is fostering new hope across diverse therapeutic areas, including oncology and rare diseases.

In Depth

Key Findings

As of the latest data update on July 15, 2026, the total number of Regenerative Medicine Advanced Therapy (RMAT) designations publicly announced by the U.S. FDA has reached 165 since the program’s inception. This designation, aimed at accelerating the market entry of innovative regenerative medicine products, signals robust growth within the sector. Notably, Rocket Pharmaceuticals has secured 5 RMAT designations, and CRISPR Therapeutics has obtained 4, establishing them as key innovators in this rapidly evolving field.

Technical / Clinical Details

RMAT designation is granted to regenerative medicine products—including cell therapies, gene therapies, tissue-engineered products, and combination products derived from cells or tissues—intended to treat serious or life-threatening diseases. This designation provides significant benefits, such as intensive FDA guidance, early and frequent interactions, expedited review, and eligibility for breakthrough therapy designation, collectively streamlining the approval process. Products qualifying for RMAT often demonstrate early clinical data indicating a clinically meaningful improvement over existing therapies, thereby accelerating patient access to promising treatments.

Background & Context

The FDA’s RMAT designation program was established in 2017 under the 21st Century Cures Act. Its primary objective is to respond to the rapid advancements in regenerative medicine and to reduce the time it takes for groundbreaking therapies to reach patients. The increasing number of RMAT designations not only reflects the intensified R&D in this sector but also indicates that products under development demonstrate high clinical potential from early stages. Rocket Pharmaceuticals focuses on gene therapies for rare diseases, while CRISPR Therapeutics specializes in gene-editing treatments; their multiple RMAT designations underscore the depth of their respective pipelines and technological leadership.

Strategic Significance & Outlook

The continuous rise in RMAT designations signifies further acceleration in the approval process for regenerative medicine and gene therapy products. This trend increases the likelihood of delivering more innovative treatments to patients with unmet medical needs. The trajectory of RMAT designations across diverse disease areas, including oncology, genetic disorders, and neurodegenerative diseases, will remain a key focus. The expedited market introduction of these designated products is expected to bring about transformative changes in clinical practice and patient outcomes.

Source: #

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.